Papers and publications

The large global burden of respiratory syncytial virus (RSV) respiratorytract infections in young children and older adults has gainedincreased recognition in recent years. Recent discoveries regardingthe neutralization-specifc viral epitopes of the pre-fusion...

Early-life severe respiratory syncytial virus (RSV) infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear. We aimed to assess the...

BackgroundRespiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins. MethodsIn a phase 2a randomized double-blind, placebo-controlled trial, healthy...

Over the past few years, the advent of several preventive interventions finally provides opportunities to address the burden of respiratory syncytial virus disease. However, in the past, new vaccines to prevent important respiratory illnesses were authorised and...

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved....

Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in young children. This document aims to update the consensus document published in 2014 to provide guidance on the current best practices for managing bronchiolitis in...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33...

Adda et al. investigated a potential inhibitor of respiratory syncytial virus (RSV) in a human challenge study. An inhibitor, known as EDP-938, would act in such a way whereby it would alter and interfere with a protein that allows for RSV to replicate in the human...

You Li, PhD, Xin Wang, PhD, Bingbing Cong, BMed, Shuyu Deng, BMed, Daniel R Feikin, MD, Harish Nair, PhDYou Li and co-workers investigated why RSV has rebounded after the expected local RSV season in several countries during the COVID-19 pandemic. The RSV epidemic was late in the 18 countries included, and 11 observed a rebound before September 2021. The risk of observing a rebound of RSV was 23 times higher after re-opening schools. On the contrary, an increase in temperature of 5°C decreas […]

Linssen RS, Bem RA, Kapitein B, Rengerink KO, Otten MH, den Hollander B, Bont L, van Woensel JBMHigh flow oxygen intends to decrease work of breathing and prevent respiratory failure. Despite trials have shown benefit, high flow oxygen has not brought the success hoped for as it did not decrease the need for PICU admissions. This study studied trends in 15,606 pediatric intensive care unit (PICU) admissions for (RSV) bronchiolitis in The Netherlands, France, Scotland, Belgium, Italy and Norway b […]

Li Y, Hodgson D, Wang X, Atkins KE, Feikin DR, Nair HAs soon as the temperature goes down by the end of summer and the beginning of fall, viruses are lurking around the corner. RSV is also such a virus, which has a clear seasonality in most countries. Maternal vaccination and passive immunization approaches for RSV are currently in development in clinical trials. However, both preventive measures will only offer an infant protection for approximately 3 to 5 months. Timing these defensive strateg […]

Ruckwardt TJ, Morabito KM, Phung E, Crank MC, Costner PJ, Holman LA, Chang LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Lin B, Bailer R, Chen M, Ortega-Villa AM, Nguyen T, Kumar A, Schwartz RM, Kueltzo LA, Stein JA, Carlton K, Gall JG, Nason MC, Mascola JR, Chen G, Graham BS, VRC 317 study team The Vaccine Research Center of NIH published a randomized, open-label, dose-escalation phase 1 clinical trial of the DS-Cav1 stabilized pre-F subunit vaccine. 95 healthy adu […]